Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBX-115 plus Acetazolamide in Metastatic Melanoma
NCT05470283Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OBX-115 in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events and Serious Adverse Events at 1 year. Started Sep 2022; status: active, not recruiting.
02
Drugs
OBX-115
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05470283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470283.